(PubMed) Cooper AJ, Sharp SJ, Luben RN, Khaw KT, Wareham NJ, Forouhi NG
Emerson declares having received consulting honoraria from Amylyx, AstraZeneca, Avillion, Ayala, Bayer, BeiGene, Boehringer Ingelheim, 89 Bio, BioAge, BioAtla, Bristol Meyer Squibb, BridgeBio, Daiichi Sankyo, Denovo, Fore Therapeutics, GlaxoSmithKline, Inovio, Insmed, Ipsen, Karuna, Lilly, Lundbeck, Mirati, Moderna, Novartis, Novavax, Novo Nordisk, NSABP, Pfizer, Principia, Reata, Rebiotx, Roche, Sanofi, SOLVD, Sutro Biopharma, and TG Therapeutics
Overall, these potential structural and functional abnormalities in individuals with psychiatric symptoms may disrupt glutamatergic neurotransmission and hinder mood regulation
Summary More research is needed to identify newer treatment options and inform clinical recommendations for AIWG
This may translate into a healthy body mass index (BMI)